Skip to Main Content

Paper Details

Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).
Am Heart J
10
2020
Author NameAffiliation
James E UdelsonTufts Medical Center
John C BurnettMayo Clinic
  • 1 - 2

Datasets

Release 1.2